Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma



Status:Recruiting
Conditions:Cancer, Cancer, Pancreatic Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/13/2019
Start Date:October 2016
End Date:October 2020
Contact:Kenneth Yu, MD, MSc
Phone:646-888-4188

Use our guide to learn which trials are right for you!

Pilot Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

The purpose of this study is to test any good and bad effects of the study drug called
PEGPH20. PEGPH20 alone is considered investigational. The Food and Drug Administration (FDA)
has not approved the marketing or sale of PEGPH20, but have authorized its use in research
studies with humans. PEGPH20 could shrink the cancer but it also can cause side effects.
PEGPH20 is an enzyme that breaks down a specific tissue component called hyaluronan produced
by some tumors. Pancreatic tumors often have a large amount of hyaluronan. The removal of
hyaluronan from tumors may decrease tumor growth.


Inclusion Criteria:

- Signed, written Institutional Review Board (IRB)-approved Informed Consent Form (ICF).

- Histologically confirmed locally advanced unresectable (Stage III) or Stage IV PDAC.

- Measurable or evaluable disease on computed tomography (CT) or magnetic resonance
imaging (MRI) scan per RECIST v1.1.

- For patients with locally advanced disease, no previous radiotherapy, surgery,
chemotherapy, or investigational therapy for the treatment of PDAC is permitted. For
patients with metastatic disease, prior treatment for non-metastatic disease with 5-FU
or gemictabine administered as radiation sensitizer, or as a cytotoxic therapy, in the
adjuvant setting is allowed, provided at least 6 months have elapsed since completion
of the last dose and no ≥ Grade 2 treatment-related toxicities are present.

- Karnofsky Performance Status ≥70%.

- Life expectancy ≥3 months.

- Age ≥18 years.

- A negative serum pregnancy test, if female of reproductive potential.

- Screening clinical laboratory values as follows, performed within 14 days prior to day
1:

- Total bilirubin ≤1.5 times upper limit of normal (ULN).

- Aspartate aminotransferase ([AST]; serum glutamic oxaloacetic transaminase
[SGOT]) and alanine aminotransferase ([ALT]; serum glutamic pyruvate transaminase
[SGPT]) ≤2.5 times ULN, (if liver metastases are present, then ≤5 times ULN is
allowed).

- Serum creatinine ≤2.0 mg/dL or calculated creatinine clearance ≥60 mL/min.

- Serum albumin ≥3.0 g/dL.

- Absolute neutrophil count (ANC) ≥1,500 cells/mm3.

- Platelet count ≥100,000 plt/mm3.

- Hemoglobin ≥9 g/dL

- Prothrombin time (PT)/international normalized ratio (INR) within normal limits
(±15%) or within therapeutic range if on warfarin.

- Partial thromboplastin time (PTT) within normal limits (±15%).

- For men and women of reproductive potential, agreement to use an effective
contraceptive method from the time of screening and throughout their time on study.
Effective contraceptive methods consist of prior sterilization, intra-uterine device,
oral or injectable contraceptives, and/or barrier methods. Abstinence alone is not
considered an adequate contraceptive measure for the purposes of this study.

Exclusion Criteria:

- Known central nervous system involvement or brain metastases.

- New York Heart Association Class III or IV cardiac disease or myocardial infarction
within the past 12 months.

- Known, clinically significant carotid artery disease.

- Known, increased risk of bleeding.

- Patients with TE event occurring > 6months prior to enrollment and receiving active
anticoagulation.

- Patients with any prior history of arterial thrombosis or symptomatic pulmonary
embolism.

- Patients with current use of megestrol acetate (use with 10 days of Day 1) will be
excluded.

- Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy.

- Known active infection with human immunodeficiency virus, hepatitis B, or hepatitis C.

- Known allergy to hyaluronidase.

- Patients with prosthetic heart valves

- Women currently pregnant or breastfeeding.

- Intolerance of dexamethasone.

- History of another primary cancer within the last 3 years with the exception of
non-melanoma skin cancer or curatively-treated cervical carcinoma in-situ.

- History of transient ischemic attack (TIA) or cerebrovascular accident (CVA).

- Any other disease, metabolic dysfunction, physical examination finding or clinical
laboratory finding that leads to reasonable suspicion of a disease or condition that
contraindicates the use of an investigational drug, that may affect the interpretation
of the results, or that may render the subject at high risk for treatment
complications.

- Other unspecified reasons that, in the opinion of the Investigator, make the subject
unsuitable for the study.

- Inability to comply with study and follow-up procedures as judged by the Investigator.
We found this trial at
11
sites
Rockville Centre, New York 11570
Phone: 646-888-4188
?
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Allentown, Pennsylvania 18105
Phone: 610-402-7880
?
mi
from
Allentown, PA
Click here to add this to my saved trials
136 Mountainview Boulevard
Basking Ridge, New Jersey 07920
Phone: 646-888-4188
?
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Commack, New York 11725
Phone: 646-888-4188
?
mi
from
Commack, NY
Click here to add this to my saved trials
500 Westchester Avenue
Harrison, New York 10604
Phone: 646-888-4188
?
mi
from
Harrison, NY
Click here to add this to my saved trials
Hartford, Connecticut 06102
Phone: 860-827-4170
?
mi
from
Hartford, CT
Click here to add this to my saved trials
Miami, Florida 33176
Phone: 786-373-3436
?
mi
from
Miami, FL
Click here to add this to my saved trials
Middletown, New Jersey 07748
Phone: 646-888-4188
?
mi
from
Middletown, NJ
Click here to add this to my saved trials
225 Summit Avenue
Montvale, New Jersey 07645
Phone: 646-888-4188
?
mi
from
Montvale, NJ
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Kenneth Yu, MD, M.Sc
Phone: 646-888-4188
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Uniondale, New York 11553
Phone: 646-888-4188
?
mi
from
Uniondale, NY
Click here to add this to my saved trials